Immunovaccine Inc. to Present at Biotech Showcase(TM) 2011

HALIFAX, NOVA SCOTIA--(Marketwire - January 05, 2011) - Immunovaccine Inc. (TSX VENTURE: IMV) announced today that Dr. Randal Chase, President and CEO, will present at Biotech Showcase on Tuesday, January 11, 2011 in San Francisco, CA.

The presentation will include an update on the Phase I preliminary safety results of DPX-0907, the Company’s first-in-man therapeutic cancer vaccine targeting patients with breast, ovarian and prostate cancer. Dr. Chase will also provide a corporate update on the development status of DPX-Survivac, a therapeutic cancer vaccine targeting ovarian cancer and an overview of recent partners who are applying Immunovaccine’s DepoVax™ vaccine delivery platform to additional vaccines in development.

Biotech Showcase provides companies an opportunity to present to investors and biopharmaceutical executives during the course of the annual JP Morgan Healthcare conference, the industry’s largest annual healthcare investor conference. www.biotechshowcase.com

About Immunovaccine

Immunovaccine Inc. (TSX VENTURE: IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery platform and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.